Autoimmune diseases such as multiple sclerosis and lupus are just recurrent inflammatory reactions to changing food inputs, arbitrarily grouped into disease names; lupus is treated by following the Tayebat system.
Original statement
الام اس التصلب اللوايحي ده سببه ايه او مثلا الذئبه الحمراء سببها ايه يا حبيبي اخوك انت كلها اعراض التهابيه متكرره في جسمك واحنا قسمناها بقى عملناها كاتيجوري حسب العرض اللي بيجي لك | علاج الذئبه الحمراء يمشي على النظام يمشي على النظام بس
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Autoimmune diseases such as multiple sclerosis and lupus are just recurrent inflammatory reactions to changing food inputs, arbitrarily grouped into disease names; lupus is treated by following the Tayebat system.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًاFAQs (Open source)
- Published
- 6 April 2026
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Machine-generated or CC transcript of a live stream; wording may contain transcription errors; context is conversational. original_ar joins separate verbatim passages with ' | '.
- Claimed mechanism
Variable dietary inputs trigger varying inflammatory reactions; diet removes the cause.
- Claimed health effect
Treatment of MS, lupus and other autoimmune diseases by diet.
- Population concerned
People with autoimmune diseases.
- Geographic restriction by Elawady
none found
Diverging source versions
علاج الذئبه الحمراء يمشي على النظام يمشي على النظام بس
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! الأكل وراء كل مشاكلك (Open source)
- Published
- 20 July 2025
- Timestamp
- 1:15:07 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
Scientific assessment
False – The statement contradicts the robust evidence.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Autoimmune diseases are food reactions; the diet treats lupus.
2. What is demonstrably correct?
Diet can matter in some immune-mediated diseases (e.g. coeliac disease is triggered by gluten), and inflammation is a shared feature of many diseases.
3. What is wrong or exaggerated?
MS and lupus are distinct diseases with specific autoantibodies, imaging and organ involvement, not arbitrary labels. There is no evidence that diet alone controls them; guideline treatment (hydroxychloroquine, immunosuppressants, biologics in SLE; disease-modifying therapy in MS) prevents organ damage and relapses.
4. What remains unclear?
Whether specific dietary patterns modestly help symptoms, fatigue or inflammation markers as add-ons: a 2026 meta-analysis found some diets may lower CRP in MS (low certainty; no effect on relapses shown) (I-AUTO-104).
5. Which studies support it?
None.
6. Which studies contradict it?
EULAR SLE 2023 (I-GUT-10); Cochrane MS diet 2020 (I-GUT-09); randomised withdrawal trial: stopping hydroxychloroquine in stable lupus led to flares in 16/22 vs 9/25 (RR 2.5) (I-AUTO-101); Cochrane network meta-analysis 2024: MS drugs reduce relapses by about 40-47% over 24 months (I-AUTO-102); ECTRIMS/EAN MS drug guideline (I-AUTO-103).
7. What applies to Germany and Europe?
Treatment standards in Germany/Europe follow EULAR and European MS guidelines.
8. What is known about Egypt?
Not region-specific.
9. What practical conclusion is appropriate?
A healthy diet can be added to, but must not replace, specialist treatment of autoimmune diseases.
Assessment details
- Rationale for certainty of evidence
SLE and MS are defined by specific immunological and pathological features and are managed with disease-modifying drugs that prevent organ damage (EULAR 2023 SLE recommendations). A Cochrane review of 30 dietary trials in MS found insufficient evidence that dietary interventions change relapses or disability. No trial of the Tayebat diet in any autoimmune disease exists.
- Source quality
Video statements; no evidence offered.
- Regional transferability
Not region-specific.
- Individual exceptions
Coeliac disease is a recognised autoimmune disease with a dietary trigger (gluten); this is an exception, not the rule.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.
Research question: In people with systemic lupus erythematosus or multiple sclerosis, are these diseases merely food-triggered inflammation, and can following a diet (the Tayebat system) replace immunosuppressive or disease-modifying drug treatment?
Research question in detail (PICO)
- Population
- People with SLE or MS
- Intervention or exposure
- Diet-only management (Tayebat system) / dietary interventions
- Comparison
- Guideline drug treatment (hydroxychloroquine, immunosuppressants, biologics; MS disease-modifying therapies)
- Geographic scope
- universal biology
- Outcomes
- Flares/relapses
- Organ damage, disability progression
- Inflammatory markers
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Diet and inflammation markers in MS
Pingel WR et al.. Mult Scler Relat Disord 2026 · PMID 41422672 · DOI 10.1016/j.msard.2025.106913 Meta-analysisabstract checkednewly addedSome diets (Mediterranean, plant-based, calorie-restricted) may lower CRP in people with MS.
- Actual result
- CRP reduced in 5 of 7 RCTs; leptin/adiponectin unchanged; NutriGRADE low.
- Methodological quality
- low (13 small RCTs; surrogate markers; COI of one author)
- Relevance
- indirect: diet can modulate inflammation markers, not disease course
- Limitations
- No relapse or disability outcomes.
What speaks against the claim?
Drugs for relapsing multiple sclerosis
Gonzalez-Lorenzo M et al.. Cochrane Database Syst Rev 2024 · PMID 38174776 · DOI 10.1002/14651858.CD011381.pub3 Meta-analysisabstract checkednewly addedDisease-modifying drugs strongly reduce MS relapses.
- Actual result
- Relapses at 24 months: cladribine RR 0.53 (0.44-0.64), alemtuzumab 0.57 (0.47-0.68), natalizumab 0.56 (0.48-0.65), high certainty.
- Methodological quality
- high (Cochrane NMA, 50 RCTs, 36,541 participants)
- Relevance
- direct for drug efficacy; indirect for diet
- Limitations
- Most trials industry-sponsored; little evidence beyond 2 years.
Stopping hydroxychloroquine in lupus
Canadian Hydroxychloroquine Study Group. N Engl J Med 1991 · PMID 1984192 · DOI 10.1056/NEJM199101173240303 Randomised controlled trialabstract checkednewly addedStopping hydroxychloroquine in stable lupus causes flares.
- Actual result
- Flares 16/22 (placebo) vs 9/25 (HCQ); RR 2.5 (1.08-5.58).
- Methodological quality
- high (double-blind RCT) but small
- Relevance
- direct: consequence of withdrawing standard therapy
- Limitations
- 47 patients, 24 weeks.
EULAR 2023 lupus treatment
Fanouriakis A et al.. Ann Rheum Dis 2024 · PMID 37827694 · DOI 10.1136/ard-2023-224762 Guideline / position statementfull text, structured risk-of-bias assessmentEULAR 2023: HCQ for all SLE patients, not to be stopped without unacceptable adverse effects; diet only as a non-pharmacological adjunct.
- Actual result
- 13 recommendations; HCQ discontinuation linked to flares.
- Methodological quality
- high (EULAR guideline, SLR-based)
- Relevance
- direct
- Limitations
- Guideline, not primary data.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
SLE and MS are distinct immune-mediated diseases with specific autoantibodies, imaging and pathology; drug treatment prevents flares, relapses and organ damage. Diet may modestly influence inflammation markers but has not been shown to control either disease.
Why some studies weigh more
Randomised drug trials and the Cochrane NMA (high certainty) outweigh small surrogate-marker diet trials (low certainty). No study of the Tayebat diet exists.
Is a causal relationship established? Yes, established Causal efficacy of DMTs and of continuing HCQ is established by RCTs; the claimed causal role of 'changing food inputs' as the cause of MS/SLE is not supported.
Remaining uncertainty
Whether specific dietary patterns modestly reduce fatigue or inflammation as add-ons.
Justified conclusion
Diet cannot replace treatment of lupus or MS; claiming so endangers patients.
Why do studies seem to disagree?
No real conflict: diet trials measure surrogate inflammation markers or fatigue as add-ons to drug treatment, whereas the claim concerns replacing treatment; the questions differ.
Does this depend on the country?
- General biological effects
- Universal immunology and pharmacology.
- Eating habits
- Not habit-dependent.
- Origin of the food
- Not applicable.
- Contaminants
- Not applicable.
- National production conditions
- Not applicable.
- Legal rules
- Not applicable.
- Actual monitoring data
- No Egyptian data on outcomes of diet-only management were found.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Crude RR from counts and CI log-symmetry – Crude RR 2.02 (72.7% vs 36.0%; risk difference 36.7 points, NNH about 3); reported RR 2.5 with log-symmetric CI (geometric midpoint 2.46); severe exacerbation RR 6.1 imprecise (CI includes 1). recalculated
- CI log-symmetry of NMA RRs – All checked RRs centred on their CIs; absolute effects not computable without placebo rates. recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Relapse/flare control with diet-only management vs guideline drug therapy
- Starting level
- high (randomised trials)
- Reasons for downgrading
- indirectness (no trial of diet replacing drugs; evidence comes from drug-vs-placebo and withdrawal trials)
- Reasons for upgrading
- large effect of DMTs (RR about 0.5)
- Result
- moderate
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- EULAR: EULAR recommendations for the management of SLE: 2023 update (2024) · Original publication
HCQ recommended for all patients and not to be discontinued without unacceptable adverse effects; non-pharmacological measures (healthy balanced diet) as adjuncts. - ECTRIMS/EAN: Guideline on the pharmacological treatment of people with MS (2018) · Original publication
GRADE-based recommendations for EMA-approved disease-modifying drugs (abstract read).
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | TITLE:(fasting) AND (autoimmune OR "rheumatoid arthritis" OR "multiple sclerosis" OR lupus) AND ("systematic review" OR "meta-analysis") | supporting evidence | 164 | |
| Europe PMC | 26 October 2026 | (diet OR dietary OR nutrition) AND ("systemic lupus erythematosus") AND ("systematic review" OR "meta-analysis") AND (randomized OR randomised OR trials) | supporting evidence | 4390 | |
| Europe PMC | 26 October 2026 | TITLE:"dietary interventions" AND TITLE:"lupus" | supporting evidence | 0 | |
| Europe PMC | 26 October 2026 | (fasting OR "fasting-mimicking" OR "calorie restriction" OR "ketogenic") AND ("multiple sclerosis") AND (randomized OR randomised) AND (pilot OR trial) | supporting evidence | 3554 | |
| Europe PMC | 26 October 2026 | TITLE:"multiple sclerosis" AND TITLE:("Mendelian randomization" OR "mendelian randomisation") AND (obesity OR "body mass index" OR BMI) | supporting evidence | 49 | |
| Europe PMC | 26 October 2026 | (diet OR dietary) AND ("multiple sclerosis") AND ("risk" ) AND ("umbrella review" OR "systematic review and meta-analysis") AND TITLE:(diet OR dietary) | supporting evidence | 98 | |
| Europe PMC | 26 October 2026 | TITLE:"hydroxychloroquine" AND (withdrawal OR discontinuation) AND lupus AND (randomized OR randomised) | contradicting evidence | 182 | |
| Europe PMC | 26 October 2026 | TITLE:"withdrawing hydroxychloroquine" | contradicting evidence | 1 | |
| Europe PMC | 26 October 2026 | JOURNAL:"Cochrane Database Syst Rev" AND TITLE:"relapsing-remitting multiple sclerosis" AND (immunomodulators OR "network meta-analysis") | contradicting evidence | 4 | |
| PubMed | 26 October 2026 | ECTRIMS/EAN guideline record fetched by PMID 29353550 (efetch) | guidelines | 1 | |
| PubMed | 26 October 2026 | (diet[ti] OR dietary[ti] OR fasting[ti]) AND (lupus[ti] OR "multiple sclerosis"[ti]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) | supporting evidence | 51 | |
| PubMed | 26 October 2026 | ("diet therapy"[MeSH] OR fasting[MeSH]) AND "Lupus Erythematosus, Systemic"[MeSH] AND (remission OR "disease activity") | supporting evidence | 14 | |
| PubMed | 26 October 2026 | (hydroxychloroquine[ti] OR immunosuppressive[ti]) AND lupus[ti] AND (withdrawal[ti] OR discontinuation[ti] OR tapering[ti]) | contradicting evidence | 19 | |
| PubMed | 26 October 2026 | "multiple sclerosis"[ti] AND (disease-modifying[ti] OR immunomodulators[ti]) AND (network meta-analysis[pt] OR "Cochrane Database Syst Rev"[ta]) | contradicting evidence | 23 |
Open questions
Number of patients following the system who stopped immunosuppression; no data found.
How deeply was this checked?
6 linked studies: 1 checked in full text (1 of them with a structured risk-of-bias assessment), 5 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: False (moderate)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: False (moderate)
New RCT evidence (HCQ withdrawal; Cochrane DMT NMA) strengthens the contradiction but the claim's 'diet replaces drugs' part has never been tested directly, so certainty stays moderate (indirectness).
New sources: I-AUTO-101 I-AUTO-102 I-AUTO-103 I-AUTO-104
In plain language
Multiple sclerosis and lupus are real, specific diseases in which the immune system attacks the body. Modern drugs prevent damage to the kidneys, brain and other organs. Studies of diets in multiple sclerosis have not shown that diet alone can control the disease. Treating lupus only with a diet is not supported by any study.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (5)
-
EULAR 2023 lupus treatment
Fanouriakis A et al.. Ann Rheum Dis 2024 · PMID 37827694 · DOI 10.1136/ard-2023-224762Guideline / position statementindependent cross-checkfull text, structured risk-of-bias assessmentHydroxychloroquine for all patients; immunosuppressants and biologics to control disease.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
SLE treatment.
- How was the study done?
Guideline.
- What was actually found?
Drug-based management.
- What do the results mean in everyday life?
Lupus needs medical treatment.
- What are the study's limitations?
COI.
- What does it say about Elawady's specific claim?
Contradicts C-AUTO-01.
- Do the results apply to Germany and Europe?
Applicable.
-
Diet and multiple sclerosis (Cochrane)
Parks NE et al.. Cochrane Database Syst Rev 2020 · PMID 32428983 · DOI 10.1002/14651858.CD004192.pub4Systematic reviewindependent cross-checkabstract checkedNo reliable evidence that diet changes relapses or disability in MS.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Diet in MS.
- How was the study done?
Cochrane review.
- How many people, animals or samples were studied?
30 trials.
- What was actually found?
No clear effects.
- How large was the observed effect?
RR ≈1.0.
- What do the results mean in everyday life?
Diet cannot replace MS treatment.
- What are the study's limitations?
Weak trials.
- What does it say about Elawady's specific claim?
Contradicts C-AUTO-01.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Small benefits.
-
Stopping hydroxychloroquine in lupus
Canadian Hydroxychloroquine Study Group. N Engl J Med 1991 · PMID 1984192 · DOI 10.1056/NEJM199101173240303Randomised controlled trialindependent cross-checkabstract checked★ key studyIn stable lupus, people switched to placebo had far more flares (73%) than those who kept taking hydroxychloroquine (36%).
Stopping HCQ in stable lupus doubled-to-tripled flares (16/22 vs 9/25).
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test whether HCQ can be stopped in stable lupus.
- How was the study done?
Double-blind RCT, 24 weeks.
- How many people, animals or samples were studied?
47 Canadian patients with stable SLE.
- What was actually found?
More and earlier flares after withdrawal.
- How large was the observed effect?
RR 2.5 (1.08-5.58).
- What do the results mean in everyday life?
Stopping lupus medicine leads to flares; diet should not replace it.
- What are the study's limitations?
Small, short.
- What does it say about Elawady's specific claim?
Contradicts 'lupus is treated by following the system' as a replacement for medicine.
- Do the results apply to Germany and Europe?
Applies; same physiology.
- What can explicitly not be concluded from this study?
Effects of adding a diet to HCQ.
-
Drugs for relapsing multiple sclerosis
Gonzalez-Lorenzo M et al.. Cochrane Database Syst Rev 2024 · PMID 38174776 · DOI 10.1002/14651858.CD011381.pub3Meta-analysisindependent cross-checkabstract checked★ key studySeveral MS drugs cut relapses roughly in half over two years compared with placebo.
DMTs reduce MS relapses by about 40-47% over 24 months (high certainty for several drugs).
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare MS drugs.
- How was the study done?
Cochrane network meta-analysis.
- How many people, animals or samples were studied?
50 trials, 36,541 people.
- What was actually found?
Large relapse reductions with several DMTs.
- How large was the observed effect?
RR about 0.53-0.57 at 24 months.
- What do the results mean in everyday life?
MS treatment works; it should not be replaced by diet.
- What are the study's limitations?
Industry trials; short follow-up.
- What does it say about Elawady's specific claim?
Contradicts diet as replacement therapy.
- Do the results apply to Germany and Europe?
Applies; same physiology.
- What can explicitly not be concluded from this study?
Long-term disability beyond 2-3 years.
-
European MS treatment guideline
Montalban X et al.. Mult Scler 2018 · PMID 29353550 · DOI 10.1177/1352458517751049Guideline / position statementindependent cross-checkabstract checked★ key studyEuropean neurology societies recommend disease-modifying drugs for MS.
European MS standard of care is pharmacological disease-modifying treatment.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Guide MS drug treatment.
- How was the study done?
GRADE guideline.
- How many people, animals or samples were studied?
not applicable
- What was actually found?
21 recommendations on DMDs.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
MS is treated with specific drugs.
- What are the study's limitations?
Not the newest edition.
- What does it say about Elawady's specific claim?
Contradicts diet as MS treatment.
- Do the results apply to Germany and Europe?
European standard.
- What can explicitly not be concluded from this study?
Role of diet as add-on.
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
Diet and inflammation markers in MS
Pingel WR et al.. Mult Scler Relat Disord 2026 · PMID 41422672 · DOI 10.1016/j.msard.2025.106913Meta-analysisindependent cross-checkabstract checked★ key studySome diets may lower inflammation markers in MS, but the evidence is weak and does not show effects on relapses or disability.
Some diets may lower CRP in MS (low certainty); no effect on disease outcomes shown.
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test diet effects on inflammation in MS.
- How was the study done?
Meta-analysis of 13 RCTs.
- How many people, animals or samples were studied?
891 people with MS.
- What was actually found?
CRP reduced in 5 of 7 trials.
- How large was the observed effect?
Adipokines not changed.
- What do the results mean in everyday life?
Healthy eating may be a useful addition to MS care, not a replacement.
- What are the study's limitations?
Surrogate outcomes; low certainty.
- What does it say about Elawady's specific claim?
Partly supports a role of diet in inflammation; not a cure.
- Do the results apply to Germany and Europe?
Applies; same physiology.
- What can explicitly not be concluded from this study?
Effect on relapses or disability.
No study in this group is marked as key.
Regional context
Germany / EU
Treatment standards in Germany/Europe follow EULAR and European MS guidelines.
Egypt
Not region-specific.
What applies in my country?
General scientific assessment
False This claim is false: lupus and multiple sclerosis are specific immune diseases, drug treatment prevents flares and relapses, and no study shows that a diet can replace it.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.. Fanouriakis A et al.. Ann Rheum Dis 2024 · PMID 37827694 · DOI 10.1136/ard-2023-224762
- Dietary interventions for multiple sclerosis-related outcomes.. Parks NE et al.. Cochrane Database Syst Rev 2020 · PMID 32428983 · DOI 10.1002/14651858.CD004192.pub4
- A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.. Canadian Hydroxychloroquine Study Group. N Engl J Med 1991 · PMID 1984192 · DOI 10.1056/NEJM199101173240303
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.. Gonzalez-Lorenzo M et al.. Cochrane Database Syst Rev 2024 · PMID 38174776 · DOI 10.1002/14651858.CD011381.pub3
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.. Montalban X et al.. Mult Scler 2018 · PMID 29353550 · DOI 10.1177/1352458517751049
- The effect of dietary interventions on peripheral markers of inflammation among people with multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials.. Pingel WR et al.. Mult Scler Relat Disord 2026 · PMID 41422672 · DOI 10.1016/j.msard.2025.106913